Academic Consortia: Clinical Trial Networks Karl Kieburtz, MD, MPH Director, Ctr for Human Experimental Therapeutics University of Rochester Medical Center.

Slides:

Advertisements

Similar presentations

Panel Discussion 1 George Williams Amgen. Barbara Tilley - Sample Size Estimation… Key point – considering both short term benefit of symptomatic treatment.

Advertisements

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Understanding of Informed Consent and Motivators.

The Community Engagement Studio: Strengthening Research Capacity through Community Engagement Consuelo H. Wilkins, MD, MSCI Executive Director, Meharry.

Registries, Databases & Clinical Networks David J Burn Newcastle University.

The Standards of Practice for a Tobacco Treatment Specialist (TTS) Gaylene Mooney, M.Ed., RRT-NPS, CTTS Program Director, Respiratory Therapy San Joaquin.

Chapter 8 Depression and Human Immunodeficiency Virus Francine Cournos, MD Karen McKinnon, MA Mark Bradley, MD Copyright © World Psychiatric Association.

Neurological Emergencies Treatment Trials SAEM 2006.

 What Problems Cause Distress and Impair Functioning?  What Problems Cause Distress and Impair Functioning?  Why do People Behave in Unusual Ways?

Neurological Emergency Treatment Trials Network Overview of the new network William Barsan, MD PI—NETT CCC nett.umich.edu.

Linda Chamberlain, PhD MPH IPV and Sexually Transmitted Infections/HIV MENU Overview Regional and Local Data The Impact of IPV on Women’s Health IPV and.

Cognitive Research Corporation Clinical Research Organization offering specialized expertise to fit the unique needs of each client offering specialized.

Ethical issues in disclosing AD biomarker results Helen FK Chiu Professor of Psychiatry, The Chinese University of Hong Kong.

Cahalans-Month-of-Madness/

Precision Medicine- Optimizing Patient Selection Janet Woodcock- “ How can we apply modern tools? ” Mark Rogge- “We need to understand the patients” Participant-Centered.

ME/ CFS o Identifiable o Treatable o Fundable Gordon Broderick, Ph.D. Associate Professor, Dept. of Medicine, University of Alberta (Volunteer Associate.

HIV Prevention Trials Network Update Africa Regional Working Group 20 May 2003.

Risk of Developing Alzheimer’s Disease in Persons with MCI

ONGOING CLINICAL TRIALS University of Vermont Presented by: Rup Tandan, MD, FRCP.

Diabetes Clinical and Translational Research: Rewards and Challenges Ruth S. Weinstock MD PhD Medical Director, Joslin Diabetes Center and Clinical Research.

1 Introduction to Grant Writing Beth Virnig, PhD Haitao Chu, MD, PhD University of Minnesota, School of Public Health December 11, 2013.

Fundamentals of Evaluation for Public Health Programs ROBERT FOLEY, M.ED. NIHB TRIBAL PUBLIC HEALTH SUMMIT MARCH 31,

Connecting South Carolina: The Gibbs/Hollings Cancer Center An NCCCP/NCI Designated Center Connection Anita L. Harrison, MPH Associate Director, Administration.

Evidence-based and Ethical Practice in Rehabilitation for TBI and Polytrauma James F. Malec, PhD, ABPP-Cn,Rp Research Director Rehabilitation Hospital.

Anticipated FY2016 Appropriations Agency$ Million NIH200 Cancer70 Cohort130 FDA10 Office of the Natl Coord. for Health IT (ONC) 5 TOTAL215 Mission: To.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FITBIR: A Platform for International.

Pediatric Psychopharmacology National Institute of Mental Health.

“The African American Prostate Cancer Crisis in Numbers”

Depression and Parkinson Disease: An Old Drug Still Works (Better) Summary and Comment by Jonathan Silver, MD Published in Journal Watch Psychiatry February.

CISNET and BCSC: Working Together To Model The Population Impact Breast Cancer Screening A Celebration of the Work of the Breast Cancer Surveillance Consortium.

1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.

CHP400: Community Health Program - lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past: Exposure Cross - section.

Detecting Individual Differences in Changes in Memory Functioning Dr. Len Lecci Professor of Psychology University of North Carolina Wilmington Director.

Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

Comprehensive Geriatric Assessment and the Patient- Centered Clinical Method.

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.

Depression Care Management Lessons from Project IMPACT _____________________________________________________ Jürgen Unützer, MD, MPH Professor and Vice.

Copyright © F.A. Davis Company Part I: General Concepts Chapter 1 Therapeutic Exercise: Foundational Concepts.

The Wisconsin Network for Health Research (WiNHR): Overview. An Infrastructure for Conducting Multi-Site Clinical Research across the State of Wisconsin.

CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.

Peripheral and Central Nervous System Drugs Advisory Committee Meeting - March 14, Issues Related to the Development of Drugs for the Treatment.

HIV/AIDS and Mental Health Integration: Is Something Not Right

HPTN Ethics Guidance for Research: Community Obligations Africa Regional Working Group Meeting, May 19-23, 2003 Lusaka, Zambia.

1 Research Methods in Child Psychopathology Carolyn R. Fallahi, Ph. D.

Using Multiple Data Sources to Understand Variable Interventions Bruce E. Landon, M.D., M.B.A. Harvard Medical School AcademyHealth Annual Research Meeting.

Estimating the population impact of homelessness on HIV viral suppression among people who use drugs Brandon DL Marshall, 1 Beth Elson, 1 Sabina Dobrer,

Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.

A Perspective on Family Medicine and End-of-Life and Palliative Care Peter Selwyn, M.D., M.P.H. Professor and Chairman Department of Family & Social Medicine.

Research networks in movement disorders Joaquim Ferreira, MD, PhD Instituto de Medicina Molecular Faculdade de Medicina de Lisboa.

The PRECIS-2 tool: Matching Intent with Methods David Hahn, MD, MS, WREN Director Department of Family Medicine & Community Health University.

Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.

FDA Orphan Products Natural History Grants Program An Opportunity for APBD? Harrison N. Jones, PhD Associate Professor Department of Surgery Duke University.

VACS Cancer Core Robert Dubrow, PhD, MD Founding Director

Hadley KEY SLIDES 9-5 7:45-8:15 PM

Center For Faculty Excellence: Leadership and Faculty Development

Laura Mauri, MD, MSc Brigham and Women’s Hospital

Better Lives. Together. The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward.

National and International Efforts worth knowing about

Research Overview Jacqueline French, MD Chief Scientific Officer

PPMI in the Medical Literature

JH Trial Innovation Unit (TIU)

“How Can Providers Address the Lack of R01 Studies. ” Robert H

New FDA Guidance on Early Alzheimer’s Disease

Challenges in Translational Research

Trial Funding and Engagement: The NIH Sponsored CTSA Program

Treatment for PTSD and SUD:

Offender Peer Education in the Texas Department of Criminal Justice

European Prevention Alzheimer’s Dementia

Associate professor Mark Morgan Bond University

Presentation transcript:

Academic Consortia: Clinical Trial Networks Karl Kieburtz, MD, MPH Director, Ctr for Human Experimental Therapeutics University of Rochester Medical Center Rochester, NY March 5, 2010

Clinical Trial Networks Two Recent Examples Dana Foundation/NINDS – HIV Dementia NINDS – PD program (NET-PD) General Thoughts

Clinical Trial Networks Dana Foundation interested in advancing trials in HIV dementia Consortium formed: Columbia, JHU, Rochester Natural history definitions, novel interventions

Clinical Trial Networks Recruited a large diverse group with advanced HIV Followed longitudinal clinical course Performed a series of pilot clinical trials - safety

Clinical Trial Networks Outcomes – Understanding of clinical progression Several trials completed Leveraged NIH funding (NARC, NEAD) Publications- Progression of Illness Metholodology Clinical trial results Additional studies

Factors associated with incident human immunodeficiency virus-dementia. Stern Y, McDermott MP, Albert S, et al. Archives of Neurology, 2001;58: Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Schifitto G, McDermott MP, McArthur JC, et al. Neurology 2002;58:

Clinical Trials in HIV-Associated Cognitive Impairment: Cognitive and Functional Outcomes. Schifitto G, Kieburtz K, McDermott MP, et al. Neurology 2001;54: Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment. Marder K, Albert SM, McDermott MP, et al. Neurology 2003;60:

Safety and tolerability of the antioxidant OPC in HIV- associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia & Related Cognitive Disorders. Neurology 1997;49: A randomized, double-blind, placebo-controlled trial of deprenyl & thioctic acid in human immunodeficiency virus- associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia & Related Cognitive Disorders. Neurology 1998;50: Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Schifitto G, Sacktor N, Marder K, et al. Neurology 1999;53:

Autonomic performance and DHEAS levels in HIV infect individuals: Relationship to TH1 and TH2 cytokine profile. Schifitto G, McDermott MP, Evans T, et al. Archives of Neurology 2000;57: Disease progression in HIV-Positive women with moderate to severe immunosuppression: The role of depression. Vedhara K, Schifitto G, McDermott M, et al. Behavioral Med 1999;25:43-47

Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study. Sacktor N, Schifitto G, McDermott MP, et al. Neurology 2000; 54: A randomized clinical trial of CPI-1189 for HIV- associated cognitive-motor impairment. Clifford DB, McArthur JC, Schifitto G, et al. Neurology 2002;59:

Clinical Trial Networks Resources that facilitated trials - Active cohort of research subjects to recruit - Standardized research protocol - Established funding for a series of trials - Dedicated, focused team

Clinical Trial Networks NINDS – NET-PD Program Separate RFA to establish: - clinical centers - coordination center - statistical center Task is to run a single large study and any pilot studies to define interventions and outcomes

Clinical Trial Networks NET-PD - Statistical & coordination centers identified and funded one year before sites - sites selected independent of centers - external guidance on effort (OSB, DSMB)

Clinical Trial Networks Outcomes - Group (with oversight) planned 2 pilot studies - Enrollment brisk - Outcomes achieved

A responsive outcome for Parkinson’s disease neuroprotection futility studies. J Elm, C. Goetz, B. Tilley, et al. Ann Neurol 2005;57: Optimizing the ongoing search for new treatments for Parkinson disease: Using futility designs. BC Tilley, YY Palesch, K Kiebutz, et al. Neurology 2006;66: Non-linearity of Parkinson’s clinical progression: implications for sample size calculations in clinical trials. P. Guimares, K Kieburtz, C. Goetz, et al. Clinical Trials 2005;2:

Self-reported adherence versus pill count in Parkinson’s disease: The NET-PD Experience. Elm JJ, Kamp C, Tilley BC, et al. Movement Disorders 2007;22(6): The impact of depressive symptoms in early Parkinson’s disease. Ravina B, Camicioli R, Como P, et al. Neurology 2007;69(4):342-7

Caffeine and progression of Parkinson’s disease. Simon DK, Swearingen C, Hauser RA, et al. Clin Neuropharmacology 2008;31(4): Minority enrollment in Parkinson’s disease clinical trials populations. Schneider MG, Swearingen CJ, Shulman LM, et al. Parkinsonism Relat Disorder, 2008 Aug 8 (Epub ahead of print).

Clinical Trial Networks Resources that facilitated trials: - Standardized research protocol - Performance centers individually funded - Established funding for a series of trials - Focused team

Academic Consortia General Thoughts: Structure Mind set Leadership

Academic Consortia Structure: Standardized protocol Established funding for a block of time Centers “incentivized” Core infrastructure: ‘ARO’

Academic Consortia Mind Set: Cohesion – team identity Focus – clear & limited goals Urgency – time limits Ownership – limited sponsor control unlimited sponsor participation

Academic Consortia Leadership: Well defined leadership and “followership” Opportunities for “project” leadership Strive for productivity Limit identification of program with leadership